GIS:FRA
Gilead Sciences, Inc
€131.56
arrow_downward
-1.82%(-2.44) 1D
Okt 14, 8:01:16 AM GMT+2 · EUR
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa GIS...
Buksan
€131.56
Mataas
€131.56
Mababa
€131.56
Mkt. cap
183.41B
Avg. na dami
423.00
Dami
0.00
Mataas nang 52-wk
€135.56
Mababa nang 52-wk
€97.79
Bilang ng mga empleyado
17K
Buksan
€131.56
Mataas
€131.56
Mababa
€131.56
Mkt. cap
183.41B
Avg. na dami
423.00
Dami
0.00
Mataas nang 52-wk
€135.56
Mababa nang 52-wk
€97.79
Bilang ng mga empleyado
17K
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
ad-hoc-news.de
·
2 oras ang nakalipas
Gilead extends Nurix deal. Gilead Sciences stock sits 2.76 percent below its high
ad-hoc-news.de
·
5 oras ang nakalipas
Gilead Sciences consensus target USD 160.07: stock pre-market at EUR 131.97, minus 0.70 percent
Benzinga
·
13 oras ang nakalipas
$100 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
MarketBeat
·
23 oras ang nakalipas
Erste Group Bank Comments on Gilead Sciences FY2027 Earnings
Profile
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Tungkol sa Gilead Sciences, Inc
CEODaniel O'Day
Mga Empleyado17K
ItinatagHun 22, 1987
HeadquartersFoster City, California, Estados Unidos
Sektor-
Websitegilead.com